ARIX BIOSCIENCE PLC — Board/Management Information 2018

May 31, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Arix Bioscience Plc - Lord John Hutton steps down from Board of Directors

PR Newswire

London, May 31

Lord John Hutton steps down from Board of Directors of Arix Bioscience plc

LONDON, 31 May 2018: Arix Bioscience plc (LSE: ARIX) (“Arix” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Lord Hutton is stepping down from his position as a Non-Executive Director of Arix Bioscience.

Jonathan Peacock, Chairman of Arix Bioscience, said: “It has been a great pleasure to work with Lord Hutton over the last two years. He has been an invaluable guide to me and to the Board as we have built Arix Bioscience and we will all miss his wise counsel and support. He leaves with our thanks and very best wishes.”    

For more information, please contact:

Arix Bioscience plc

Charlotte Parry, Investors Relations Manager

+44 (0) 20 7290 1072

Charlotte@arixbioscience.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com